Skip to main content

Loading market data...

ADMA

ADMA Biologics, Inc.

NASDAQ • United states

$11.07

+$0.39

(+3.65%)

Source: Yahoo Finance · Quote time Oct 19, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

ADMA Biologics, Inc. (ADMA)

Unavailable

Quotes may be delayed

$2.48B

Market Cap

2,873,690

Volume

14.7

P/E Ratio

Unavailable

Div Yield

ADMA Biologics, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: C/O ADMA BIOLOGICS, INC., RAMSEY, NJ
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

7 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in ADMA Biologics, Inc..

5 Aug 2026

ADMA Biologics, Inc. filed Form 10-Q

ADMA Biologics, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

5 Aug 2026

ADMA Biologics, Inc. reported Operating or financial results

ADMA Biologics, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

2 Jun 2026

ADMA Biologics, Inc. reported Shareholder voting results

ADMA Biologics, Inc. filed an 8-K covering shareholder voting results.

6 May 2026

ADMA Biologics, Inc. filed Form 10-Q

ADMA Biologics, Inc. submitted Form 10-Q to the SEC for the period ending Mar 31, 2026.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$136.02M

Total assets (USD)$684.21M

Total liabilities (USD)$276.00M

Shareholders' equity (USD)$408.21M

Long-term debt (USD)$192.84M

Debt due within a year (USD)$3.75M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$124.40M	$52.45M	$37.82M	$0.16	10-Q · 5 Aug 2026
Q1 2026	$114.49M	$58.27M	$45.33M	$0.19	10-Q · 6 May 2026
Q4 2025	$139.16M	$62.75M	$49.38M	Unavailable	10-K · 25 Feb 2026
Q3 2025	$134.22M	$51.01M	$36.43M	$0.15	10-Q · 5 Nov 2025
Q2 2025	$121.98M	$42.80M	$34.22M	$0.14	10-Q · 6 Aug 2025
Q1 2025	$114.80M	$34.88M	$26.90M	$0.11	10-Q · 7 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $15.00

35.5% upside potential

📈

Strong Buy

Unavailable

👍

Buy

1

⏸️

Hold

1

📉

Sell

0

2 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 11:47 UTC Targets range 12.00–18.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

24

Jul 2026

Kestenberg-Messina Kaitlin M.

COO and SVP, Compliance

Tax withholding

$8.37 per share

3,177 shares

16

Jul 2026

Kohler Terry

CFO and Treasurer

Grant or award

Unavailable per share

85,130 shares

27

May 2026

Grossman Jerrold B

Director

Open-market purchase

$7.91 per share

6,400 shares

12

May 2026

Grossman Jerrold B

Director

Open-market purchase

$8.01 per share

12,500 shares

11

May 2026

Grossman Jerrold B

Director

Open-market purchase

$8.01 per share

12,500 shares

1

Apr 2026

Kestenberg-Messina Kaitlin M.

COO and SVP, Compliance

Tax withholding

$9.11 per share

20,362 shares

17

Mar 2026

Guiheen Lawrence P.

Director

Gift

Unavailable per share

60,000 shares

16

Mar 2026

Grossman Adam S

Director, President and CEO

Option exercise

$5.40 per share

15,000 shares

16

Mar 2026

Grossman Adam S

Director, President and CEO

Open-market sale

$15.16 per share

21,000 shares

13

Mar 2026

Guiheen Lawrence P.

Director

Option exercise

$3.66 per share

30,000 shares

Top Shareholders

Blackrock, Inc.

38,355,684 shares

4.14% change

6/30/2026

Vanguard Group Inc

20,854,669 shares

-0.574% change

12/31/2025

State Street Corp

17,116,022 shares

21.526% change

6/30/2026

Vanguard Capital Management Llc

10,103,809 shares

-1.97% change

6/30/2026

Vanguard Portfolio Management Llc

10,088,490 shares

13.754% change

6/30/2026

Rubric Capital Management Lp

9,339,414 shares

416.159% change

6/30/2026

Capital Research Global Investors

8,756,374 shares

-21.756% change

6/30/2026

First Trust Advisors Lp

7,798,351 shares

2064.904% change

6/30/2026

Geode Capital Management, Llc

6,059,984 shares

4.05% change

6/30/2026

Caligan Partners Lp

5,725,007 shares

20.361% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 11:47 UTC· 1 day ago

Research coverage and investment tools

ADMA Biologics, Inc. (ADMA) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)). Its last price was US$11.07 on 19 Oct 2026. That is 29% of the way from its 52-week low of US$7.21 to its 52-week high of US$20.46. Its market capitalisation was US$2.48 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$124.40M	$52.45M	$37.82M	$0.16	69.4%	42.2%	$27.28M	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$114.49M	$58.27M	$45.33M	$0.19	70.5%	50.9%	$55.71M	10-Q · 6 May 2026 (opens in a new tab)
Q4 2025	$139.16M	$62.75M	$49.38M	Unavailable	63.8%	45.1%	$34.56M	10-K · 25 Feb 2026 (opens in a new tab)
Q3 2025	$134.22M	$51.01M	$36.43M	$0.15	56.3%	38.0%	−$1.08M	10-Q · 5 Nov 2025 (opens in a new tab)
Q2 2025	$121.98M	$42.80M	$34.22M	$0.14	55.1%	35.1%	$18.72M	10-Q · 6 Aug 2025 (opens in a new tab)
Q1 2025	$114.80M	$34.88M	$26.90M	$0.11	53.2%	30.4%	−$24.38M	10-Q · 7 May 2025 (opens in a new tab)

Cash and equivalents: $136.02M
Total assets: $684.21M
Total liabilities: $276.00M
Shareholders' equity: $408.21M
Long-term debt: $192.84M
Debt due within a year: $3.75M

SCHEDULE 13G · 7 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in ADMA Biologics, Inc..
10-Q · 5 Aug 2026

ADMA Biologics, Inc. filed Form 10-Q (opens in a new tab)

ADMA Biologics, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 5 Aug 2026

ADMA Biologics, Inc. reported Operating or financial results (opens in a new tab)

ADMA Biologics, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
8-K · 2 Jun 2026

ADMA Biologics, Inc. reported Shareholder voting results (opens in a new tab)

ADMA Biologics, Inc. filed an 8-K covering shareholder voting results.
10-Q · 6 May 2026

ADMA Biologics, Inc. filed Form 10-Q (opens in a new tab)

ADMA Biologics, Inc. submitted Form 10-Q to the SEC for the period ending Mar 31, 2026.

Insider	Date	Transaction	Shares	Average price	Filing
Kestenberg-Messina Kaitlin M. COO and SVP, Compliance	24 Jul 2026	Tax withholding (F)	−3,177	$8.37	Form 4 (opens in a new tab)
Kohler Terry CFO and Treasurer	16 Jul 2026	Grant or award (A)	+85,130	—	Form 4 (opens in a new tab)
Grossman Jerrold B Director	27 May 2026	Open-market purchase (P)	+6,400	$7.91	Form 4 (opens in a new tab)
Grossman Jerrold B Director	12 May 2026	Open-market purchase (P)	+12,500	$8.01	Form 4 (opens in a new tab)
Grossman Jerrold B Director	11 May 2026	Open-market purchase (P)	+12,500	$8.01	Form 4 (opens in a new tab)
Kestenberg-Messina Kaitlin M. COO and SVP, Compliance	1 Apr 2026	Tax withholding (F)	−20,362	$9.11	Form 4 (opens in a new tab)
Guiheen Lawrence P. Director	17 Mar 2026	Gift (G)	−60,000	—	Form 4 (opens in a new tab)
Grossman Adam S Director, President and CEO	16 Mar 2026	Option exercise (M)	+15,000	$5.40	Form 4 (opens in a new tab)
Grossman Adam S Director, President and CEO	16 Mar 2026	Open-market sale (S)	−21,000	$15.16	Form 4 (opens in a new tab)
Guiheen Lawrence P. Director	13 Mar 2026	Option exercise (M)	+30,000	$3.66	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	38,355,684	4.14%
Vanguard Group Inc	12/31/2025	20,854,669	-0.574%
State Street Corp	6/30/2026	17,116,022	21.526%
Vanguard Capital Management Llc	6/30/2026	10,103,809	-1.97%
Vanguard Portfolio Management Llc	6/30/2026	10,088,490	13.754%
Rubric Capital Management Lp	6/30/2026	9,339,414	416.159%
Capital Research Global Investors	6/30/2026	8,756,374	-21.756%
First Trust Advisors Lp	6/30/2026	7,798,351	2064.904%
Geode Capital Management, Llc	6/30/2026	6,059,984	4.05%
Caligan Partners Lp	6/30/2026	5,725,007	20.361%

Previous close: 10.68 USD
Day range: 10.68 – 11.14 USD
52-week range: 7.21 – 20.46 USD
Volume: 2,873,690
Market cap: $2.48B
Average volume: 2,632,030
P/E ratio: 14.7
EPS (FY 2025, diluted): 0.60 USD
Shares outstanding: 223.98M
Beta (5Y monthly): 0.67

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 19 Oct 2026, 20:00 UTC· 2 days ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 08:07 UTC· 3 hours ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for ADMA yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.